Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 7, 2001, Pages 600-603

  Kobylinska K ^a   Koralewski, P ^a   Sobik, B ^a   Gasiorek M ^a   Kobylinska M ^a  

^a INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Bromofosfamide, clinical, pharmacokinetics, toxicity; CAS 146452 37 1; CBM 11; Cytostatics; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOFOSFAMIDE; CBM 11; IFOSFAMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEPHROTOXICITY; NEUROTOXICITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET RADIATION;

EID: 0034922152     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300086     Document Type: Article

References (6)

1. Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds
2. Oral chemotherapy: Rationale and future directions
3. Pharmacokinetics and bioavailability of oral ifosfamide
4. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma